- Amlan has expanded its broad portfolio of animal health feed additives to include a natural alternative to anticoccidial drugs and vaccines and a natural pathogen control product for antibiotic-free production.
- Increasing demand for antibiotic-free production has created the need for solutions like Phylox® Feed and NeutraPath® that can reduce the negative health and production effects of enteric disease.
- The new products are commercially available in select international markets and can be used alone or in combination with products from Amlan’s comprehensive range of mineral-based feed additives.
The removal of in-feed antibiotics from poultry and livestock production has left a huge gap in the protection of animals from the devastating effects of enteric disease. To help producers recapture this protection, Amlan International, the animal health business of Oil-Dri® Corporation of America, has launched two new natural products — Phylox® Feed and NeutraPath® — that help optimize intestinal health and production economics in the absence of antibiotics.
Phylox Feed is a natural alternative to anticoccidial drugs and vaccines that can help producers increase profitability. Coccidiosis, caused by Eimeria species, is an enteric disease that can have a significant economic impact on animal protein production. The synergistic blend of bioactive phytochemicals in Phylox work together with multiple modes of action to damage Eimeria cell structure and function while strengthening intestinal integrity and boosting immunity. Phylox can be effective for full-time use or in rotation, and/or in a bio-shuttle program when resistance is a concern. In addition, Phylox does not need to be withdrawn from feed prior to slaughter. Phylox is an ideal solution for all poultry species, including broilers, egg layers and broiler breeders, all of which can be sensitive to fungal and bacterial toxins during grow-out and egg production when exposed to fecal oocysts that are being shed as coccidia cycle. Research has shown that Phylox can be fed concurrently with anticoccidial vaccines, preventing disease breakthrough while immunity is being developed by the bird without interfering with vaccine efficacy.
“Managing enteric disease without antibiotics has placed extra pressure on nutritionists and veterinarians to find natural solutions that can achieve the same level of performance observed with antibiotic use,” said Dr. Wade Robey, VP of Marketing and Product Development for Amlan. “NeutraPath has answered the call for a natural product that targets pathogens and the toxins they produce — and it improves intestinal health, as well. It’s the natural alternative to antibiotics that the animal protein industry has been waiting for.”
NeutraPath can be used to protect the intestinal health of all livestock species. The Journal of Animal Science recently published a study by UC Davis researchers on the effects of NeutraPath in weaned pigs challenged with enterotoxigenic E. coli. NeutraPath reduced the incidence of severe diarrhea, enhanced feed efficiency during the last week of the study and modified fecal and ileal mucosa microbiota diversity.
Amlan invests heavily in R&D to produce well-validated products both in vitro and in animals, and they are also working directly with customers to assess the commercial performance of their new products. Producers interested in testing the products for themselves can contact Amlan at info@amlan.com.
